The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience
Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jedd...
Ausführliche Beschreibung
Autor*in: |
Alobaidi S [verfasserIn] Dwid N [verfasserIn] Shikh Souk K [verfasserIn] Cheikh M [verfasserIn] Mandurah A [verfasserIn] Al-Khatib K [verfasserIn] Ahmed A [verfasserIn] Almoallim H [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2021 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: International Journal of General Medicine - Dove Medical Press, 2008, (2021), Seite 1141-1146 |
---|---|
Übergeordnetes Werk: |
year:2021 ; pages:1141-1146 |
Links: |
---|
Katalog-ID: |
DOAJ048712639 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ048712639 | ||
003 | DE-627 | ||
005 | 20230308135547.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2021 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)DOAJ048712639 | ||
035 | |a (DE-599)DOAJde67e80ae4ad454988191b61a5d96232 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a R5-920 | |
100 | 0 | |a Alobaidi S |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 3Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 4Doctor Soliman Fakeeh Hospital, Rheumatology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 5Medical College, Umm Alqura University (UQU), Makkah, 21441, Saudi ArabiaCorrespondence: Sami AlobaidiDepartment of Medicine, University of Jeddah, Jeddah, Saudi ArabiaEmail salobaidiuj.edu.saContext: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). Although it is associated with CKD incidence and progression, treating asymptomatic hyperuricemia with uric acid-lowering agents is still debatable.Aim of Work: determine the rate of non-classical prescription of allopurinol in CKD patients.Settings and Design: This was a retrospective study of adult patients prescribed allopurinol with CKD (stages 2– 5) in Doctor Soliman Fakeeh Hospital (DSFH) Jeddah, Saudi Arabia, from 1/1/2016 to 1/1/2017.Subjects and Methods: Eligible patients were identified from the hospital’s pharmacy system and cross-referenced with the electronic health records. Demographic data, laboratory results and indication as recorded by the prescribing physician were extracted. Prescriptions with no indication were categorized based on the uric acid levels. Hyperuricemia was documented as mild (6– 10 mg/dL in females and 7– 13 mg/dL in males) and severe (> 13mg/dL in men and > 10mg/dL in women).Statistical Analysis Used: Descriptive statistics (frequencies, percentages).Results: From the 594 identified patients, 464 (78.1%) were males. A third of prescriptions (209/594) had no indication, 43.5% of which (91/209) had no documented uric acid levels, and 16.3% (34/209) had normal levels. Including patients with undocumented indication, 64.2% (381/594) were prescribed allopurinol for hyperuricemia, 86.4% of which (329/381) had mild hyperuricemia, and only 13.6% (52/381) had severe hyperuricemia. Other indications included malignancy-related disorders (6.2%, 37/594), gouty arthritis (5.2%, 31/594), and stones of unknown aetiology (3.4%, 20/594).Conclusion: The percentage of allopurinol prescription to patients with CKD without a clear indication in our centre was markedly high. This might increase the risk for side effects with no evidence-based benefits.Keywords: allopurinol, gout, hyperuricemia, hyperuricosuria, over prescription, chronic kidney disease | ||
650 | 4 | |a allopurinol | |
650 | 4 | |a gout | |
650 | 4 | |a hyperuricemia | |
650 | 4 | |a hyperuricosuria | |
650 | 4 | |a over prescription | |
650 | 4 | |a chronic kidney disease. | |
653 | 0 | |a Medicine (General) | |
700 | 0 | |a Dwid N |e verfasserin |4 aut | |
700 | 0 | |a Shikh Souk K |e verfasserin |4 aut | |
700 | 0 | |a Cheikh M |e verfasserin |4 aut | |
700 | 0 | |a Mandurah A |e verfasserin |4 aut | |
700 | 0 | |a Al-Khatib K |e verfasserin |4 aut | |
700 | 0 | |a Ahmed A |e verfasserin |4 aut | |
700 | 0 | |a Almoallim H |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t International Journal of General Medicine |d Dove Medical Press, 2008 |g (2021), Seite 1141-1146 |w (DE-627)578539691 |w (DE-600)2452220-X |x 11787074 |7 nnns |
773 | 1 | 8 | |g year:2021 |g pages:1141-1146 |
856 | 4 | 0 | |u https://doaj.org/article/de67e80ae4ad454988191b61a5d96232 |z kostenfrei |
856 | 4 | 0 | |u https://www.dovepress.com/the-pattern-of-allopurinol-prescription-among-chronic-kidney-disease-p-peer-reviewed-article-IJGM |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1178-7074 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |j 2021 |h 1141-1146 |
author_variant |
a s as d n dn s s k ssk c m cm m a ma a k k akk a a aa a h ah |
---|---|
matchkey_str |
article:11787074:2021----::hptenflouiopecitoaoghoikdedsaeainsntrircrc |
hierarchy_sort_str |
2021 |
callnumber-subject-code |
R |
publishDate |
2021 |
allfields |
(DE-627)DOAJ048712639 (DE-599)DOAJde67e80ae4ad454988191b61a5d96232 DE-627 ger DE-627 rakwb eng R5-920 Alobaidi S verfasserin aut The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 3Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 4Doctor Soliman Fakeeh Hospital, Rheumatology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 5Medical College, Umm Alqura University (UQU), Makkah, 21441, Saudi ArabiaCorrespondence: Sami AlobaidiDepartment of Medicine, University of Jeddah, Jeddah, Saudi ArabiaEmail salobaidiuj.edu.saContext: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). Although it is associated with CKD incidence and progression, treating asymptomatic hyperuricemia with uric acid-lowering agents is still debatable.Aim of Work: determine the rate of non-classical prescription of allopurinol in CKD patients.Settings and Design: This was a retrospective study of adult patients prescribed allopurinol with CKD (stages 2– 5) in Doctor Soliman Fakeeh Hospital (DSFH) Jeddah, Saudi Arabia, from 1/1/2016 to 1/1/2017.Subjects and Methods: Eligible patients were identified from the hospital’s pharmacy system and cross-referenced with the electronic health records. Demographic data, laboratory results and indication as recorded by the prescribing physician were extracted. Prescriptions with no indication were categorized based on the uric acid levels. Hyperuricemia was documented as mild (6– 10 mg/dL in females and 7– 13 mg/dL in males) and severe (> 13mg/dL in men and > 10mg/dL in women).Statistical Analysis Used: Descriptive statistics (frequencies, percentages).Results: From the 594 identified patients, 464 (78.1%) were males. A third of prescriptions (209/594) had no indication, 43.5% of which (91/209) had no documented uric acid levels, and 16.3% (34/209) had normal levels. Including patients with undocumented indication, 64.2% (381/594) were prescribed allopurinol for hyperuricemia, 86.4% of which (329/381) had mild hyperuricemia, and only 13.6% (52/381) had severe hyperuricemia. Other indications included malignancy-related disorders (6.2%, 37/594), gouty arthritis (5.2%, 31/594), and stones of unknown aetiology (3.4%, 20/594).Conclusion: The percentage of allopurinol prescription to patients with CKD without a clear indication in our centre was markedly high. This might increase the risk for side effects with no evidence-based benefits.Keywords: allopurinol, gout, hyperuricemia, hyperuricosuria, over prescription, chronic kidney disease allopurinol gout hyperuricemia hyperuricosuria over prescription chronic kidney disease. Medicine (General) Dwid N verfasserin aut Shikh Souk K verfasserin aut Cheikh M verfasserin aut Mandurah A verfasserin aut Al-Khatib K verfasserin aut Ahmed A verfasserin aut Almoallim H verfasserin aut In International Journal of General Medicine Dove Medical Press, 2008 (2021), Seite 1141-1146 (DE-627)578539691 (DE-600)2452220-X 11787074 nnns year:2021 pages:1141-1146 https://doaj.org/article/de67e80ae4ad454988191b61a5d96232 kostenfrei https://www.dovepress.com/the-pattern-of-allopurinol-prescription-among-chronic-kidney-disease-p-peer-reviewed-article-IJGM kostenfrei https://doaj.org/toc/1178-7074 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2021 1141-1146 |
spelling |
(DE-627)DOAJ048712639 (DE-599)DOAJde67e80ae4ad454988191b61a5d96232 DE-627 ger DE-627 rakwb eng R5-920 Alobaidi S verfasserin aut The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 3Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 4Doctor Soliman Fakeeh Hospital, Rheumatology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 5Medical College, Umm Alqura University (UQU), Makkah, 21441, Saudi ArabiaCorrespondence: Sami AlobaidiDepartment of Medicine, University of Jeddah, Jeddah, Saudi ArabiaEmail salobaidiuj.edu.saContext: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). Although it is associated with CKD incidence and progression, treating asymptomatic hyperuricemia with uric acid-lowering agents is still debatable.Aim of Work: determine the rate of non-classical prescription of allopurinol in CKD patients.Settings and Design: This was a retrospective study of adult patients prescribed allopurinol with CKD (stages 2– 5) in Doctor Soliman Fakeeh Hospital (DSFH) Jeddah, Saudi Arabia, from 1/1/2016 to 1/1/2017.Subjects and Methods: Eligible patients were identified from the hospital’s pharmacy system and cross-referenced with the electronic health records. Demographic data, laboratory results and indication as recorded by the prescribing physician were extracted. Prescriptions with no indication were categorized based on the uric acid levels. Hyperuricemia was documented as mild (6– 10 mg/dL in females and 7– 13 mg/dL in males) and severe (> 13mg/dL in men and > 10mg/dL in women).Statistical Analysis Used: Descriptive statistics (frequencies, percentages).Results: From the 594 identified patients, 464 (78.1%) were males. A third of prescriptions (209/594) had no indication, 43.5% of which (91/209) had no documented uric acid levels, and 16.3% (34/209) had normal levels. Including patients with undocumented indication, 64.2% (381/594) were prescribed allopurinol for hyperuricemia, 86.4% of which (329/381) had mild hyperuricemia, and only 13.6% (52/381) had severe hyperuricemia. Other indications included malignancy-related disorders (6.2%, 37/594), gouty arthritis (5.2%, 31/594), and stones of unknown aetiology (3.4%, 20/594).Conclusion: The percentage of allopurinol prescription to patients with CKD without a clear indication in our centre was markedly high. This might increase the risk for side effects with no evidence-based benefits.Keywords: allopurinol, gout, hyperuricemia, hyperuricosuria, over prescription, chronic kidney disease allopurinol gout hyperuricemia hyperuricosuria over prescription chronic kidney disease. Medicine (General) Dwid N verfasserin aut Shikh Souk K verfasserin aut Cheikh M verfasserin aut Mandurah A verfasserin aut Al-Khatib K verfasserin aut Ahmed A verfasserin aut Almoallim H verfasserin aut In International Journal of General Medicine Dove Medical Press, 2008 (2021), Seite 1141-1146 (DE-627)578539691 (DE-600)2452220-X 11787074 nnns year:2021 pages:1141-1146 https://doaj.org/article/de67e80ae4ad454988191b61a5d96232 kostenfrei https://www.dovepress.com/the-pattern-of-allopurinol-prescription-among-chronic-kidney-disease-p-peer-reviewed-article-IJGM kostenfrei https://doaj.org/toc/1178-7074 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2021 1141-1146 |
allfields_unstemmed |
(DE-627)DOAJ048712639 (DE-599)DOAJde67e80ae4ad454988191b61a5d96232 DE-627 ger DE-627 rakwb eng R5-920 Alobaidi S verfasserin aut The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 3Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 4Doctor Soliman Fakeeh Hospital, Rheumatology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 5Medical College, Umm Alqura University (UQU), Makkah, 21441, Saudi ArabiaCorrespondence: Sami AlobaidiDepartment of Medicine, University of Jeddah, Jeddah, Saudi ArabiaEmail salobaidiuj.edu.saContext: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). Although it is associated with CKD incidence and progression, treating asymptomatic hyperuricemia with uric acid-lowering agents is still debatable.Aim of Work: determine the rate of non-classical prescription of allopurinol in CKD patients.Settings and Design: This was a retrospective study of adult patients prescribed allopurinol with CKD (stages 2– 5) in Doctor Soliman Fakeeh Hospital (DSFH) Jeddah, Saudi Arabia, from 1/1/2016 to 1/1/2017.Subjects and Methods: Eligible patients were identified from the hospital’s pharmacy system and cross-referenced with the electronic health records. Demographic data, laboratory results and indication as recorded by the prescribing physician were extracted. Prescriptions with no indication were categorized based on the uric acid levels. Hyperuricemia was documented as mild (6– 10 mg/dL in females and 7– 13 mg/dL in males) and severe (> 13mg/dL in men and > 10mg/dL in women).Statistical Analysis Used: Descriptive statistics (frequencies, percentages).Results: From the 594 identified patients, 464 (78.1%) were males. A third of prescriptions (209/594) had no indication, 43.5% of which (91/209) had no documented uric acid levels, and 16.3% (34/209) had normal levels. Including patients with undocumented indication, 64.2% (381/594) were prescribed allopurinol for hyperuricemia, 86.4% of which (329/381) had mild hyperuricemia, and only 13.6% (52/381) had severe hyperuricemia. Other indications included malignancy-related disorders (6.2%, 37/594), gouty arthritis (5.2%, 31/594), and stones of unknown aetiology (3.4%, 20/594).Conclusion: The percentage of allopurinol prescription to patients with CKD without a clear indication in our centre was markedly high. This might increase the risk for side effects with no evidence-based benefits.Keywords: allopurinol, gout, hyperuricemia, hyperuricosuria, over prescription, chronic kidney disease allopurinol gout hyperuricemia hyperuricosuria over prescription chronic kidney disease. Medicine (General) Dwid N verfasserin aut Shikh Souk K verfasserin aut Cheikh M verfasserin aut Mandurah A verfasserin aut Al-Khatib K verfasserin aut Ahmed A verfasserin aut Almoallim H verfasserin aut In International Journal of General Medicine Dove Medical Press, 2008 (2021), Seite 1141-1146 (DE-627)578539691 (DE-600)2452220-X 11787074 nnns year:2021 pages:1141-1146 https://doaj.org/article/de67e80ae4ad454988191b61a5d96232 kostenfrei https://www.dovepress.com/the-pattern-of-allopurinol-prescription-among-chronic-kidney-disease-p-peer-reviewed-article-IJGM kostenfrei https://doaj.org/toc/1178-7074 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2021 1141-1146 |
allfieldsGer |
(DE-627)DOAJ048712639 (DE-599)DOAJde67e80ae4ad454988191b61a5d96232 DE-627 ger DE-627 rakwb eng R5-920 Alobaidi S verfasserin aut The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 3Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 4Doctor Soliman Fakeeh Hospital, Rheumatology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 5Medical College, Umm Alqura University (UQU), Makkah, 21441, Saudi ArabiaCorrespondence: Sami AlobaidiDepartment of Medicine, University of Jeddah, Jeddah, Saudi ArabiaEmail salobaidiuj.edu.saContext: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). Although it is associated with CKD incidence and progression, treating asymptomatic hyperuricemia with uric acid-lowering agents is still debatable.Aim of Work: determine the rate of non-classical prescription of allopurinol in CKD patients.Settings and Design: This was a retrospective study of adult patients prescribed allopurinol with CKD (stages 2– 5) in Doctor Soliman Fakeeh Hospital (DSFH) Jeddah, Saudi Arabia, from 1/1/2016 to 1/1/2017.Subjects and Methods: Eligible patients were identified from the hospital’s pharmacy system and cross-referenced with the electronic health records. Demographic data, laboratory results and indication as recorded by the prescribing physician were extracted. Prescriptions with no indication were categorized based on the uric acid levels. Hyperuricemia was documented as mild (6– 10 mg/dL in females and 7– 13 mg/dL in males) and severe (> 13mg/dL in men and > 10mg/dL in women).Statistical Analysis Used: Descriptive statistics (frequencies, percentages).Results: From the 594 identified patients, 464 (78.1%) were males. A third of prescriptions (209/594) had no indication, 43.5% of which (91/209) had no documented uric acid levels, and 16.3% (34/209) had normal levels. Including patients with undocumented indication, 64.2% (381/594) were prescribed allopurinol for hyperuricemia, 86.4% of which (329/381) had mild hyperuricemia, and only 13.6% (52/381) had severe hyperuricemia. Other indications included malignancy-related disorders (6.2%, 37/594), gouty arthritis (5.2%, 31/594), and stones of unknown aetiology (3.4%, 20/594).Conclusion: The percentage of allopurinol prescription to patients with CKD without a clear indication in our centre was markedly high. This might increase the risk for side effects with no evidence-based benefits.Keywords: allopurinol, gout, hyperuricemia, hyperuricosuria, over prescription, chronic kidney disease allopurinol gout hyperuricemia hyperuricosuria over prescription chronic kidney disease. Medicine (General) Dwid N verfasserin aut Shikh Souk K verfasserin aut Cheikh M verfasserin aut Mandurah A verfasserin aut Al-Khatib K verfasserin aut Ahmed A verfasserin aut Almoallim H verfasserin aut In International Journal of General Medicine Dove Medical Press, 2008 (2021), Seite 1141-1146 (DE-627)578539691 (DE-600)2452220-X 11787074 nnns year:2021 pages:1141-1146 https://doaj.org/article/de67e80ae4ad454988191b61a5d96232 kostenfrei https://www.dovepress.com/the-pattern-of-allopurinol-prescription-among-chronic-kidney-disease-p-peer-reviewed-article-IJGM kostenfrei https://doaj.org/toc/1178-7074 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2021 1141-1146 |
allfieldsSound |
(DE-627)DOAJ048712639 (DE-599)DOAJde67e80ae4ad454988191b61a5d96232 DE-627 ger DE-627 rakwb eng R5-920 Alobaidi S verfasserin aut The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 3Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 4Doctor Soliman Fakeeh Hospital, Rheumatology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 5Medical College, Umm Alqura University (UQU), Makkah, 21441, Saudi ArabiaCorrespondence: Sami AlobaidiDepartment of Medicine, University of Jeddah, Jeddah, Saudi ArabiaEmail salobaidiuj.edu.saContext: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). Although it is associated with CKD incidence and progression, treating asymptomatic hyperuricemia with uric acid-lowering agents is still debatable.Aim of Work: determine the rate of non-classical prescription of allopurinol in CKD patients.Settings and Design: This was a retrospective study of adult patients prescribed allopurinol with CKD (stages 2– 5) in Doctor Soliman Fakeeh Hospital (DSFH) Jeddah, Saudi Arabia, from 1/1/2016 to 1/1/2017.Subjects and Methods: Eligible patients were identified from the hospital’s pharmacy system and cross-referenced with the electronic health records. Demographic data, laboratory results and indication as recorded by the prescribing physician were extracted. Prescriptions with no indication were categorized based on the uric acid levels. Hyperuricemia was documented as mild (6– 10 mg/dL in females and 7– 13 mg/dL in males) and severe (> 13mg/dL in men and > 10mg/dL in women).Statistical Analysis Used: Descriptive statistics (frequencies, percentages).Results: From the 594 identified patients, 464 (78.1%) were males. A third of prescriptions (209/594) had no indication, 43.5% of which (91/209) had no documented uric acid levels, and 16.3% (34/209) had normal levels. Including patients with undocumented indication, 64.2% (381/594) were prescribed allopurinol for hyperuricemia, 86.4% of which (329/381) had mild hyperuricemia, and only 13.6% (52/381) had severe hyperuricemia. Other indications included malignancy-related disorders (6.2%, 37/594), gouty arthritis (5.2%, 31/594), and stones of unknown aetiology (3.4%, 20/594).Conclusion: The percentage of allopurinol prescription to patients with CKD without a clear indication in our centre was markedly high. This might increase the risk for side effects with no evidence-based benefits.Keywords: allopurinol, gout, hyperuricemia, hyperuricosuria, over prescription, chronic kidney disease allopurinol gout hyperuricemia hyperuricosuria over prescription chronic kidney disease. Medicine (General) Dwid N verfasserin aut Shikh Souk K verfasserin aut Cheikh M verfasserin aut Mandurah A verfasserin aut Al-Khatib K verfasserin aut Ahmed A verfasserin aut Almoallim H verfasserin aut In International Journal of General Medicine Dove Medical Press, 2008 (2021), Seite 1141-1146 (DE-627)578539691 (DE-600)2452220-X 11787074 nnns year:2021 pages:1141-1146 https://doaj.org/article/de67e80ae4ad454988191b61a5d96232 kostenfrei https://www.dovepress.com/the-pattern-of-allopurinol-prescription-among-chronic-kidney-disease-p-peer-reviewed-article-IJGM kostenfrei https://doaj.org/toc/1178-7074 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2021 1141-1146 |
language |
English |
source |
In International Journal of General Medicine (2021), Seite 1141-1146 year:2021 pages:1141-1146 |
sourceStr |
In International Journal of General Medicine (2021), Seite 1141-1146 year:2021 pages:1141-1146 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
allopurinol gout hyperuricemia hyperuricosuria over prescription chronic kidney disease. Medicine (General) |
isfreeaccess_bool |
true |
container_title |
International Journal of General Medicine |
authorswithroles_txt_mv |
Alobaidi S @@aut@@ Dwid N @@aut@@ Shikh Souk K @@aut@@ Cheikh M @@aut@@ Mandurah A @@aut@@ Al-Khatib K @@aut@@ Ahmed A @@aut@@ Almoallim H @@aut@@ |
publishDateDaySort_date |
2021-01-01T00:00:00Z |
hierarchy_top_id |
578539691 |
id |
DOAJ048712639 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ048712639</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308135547.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ048712639</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJde67e80ae4ad454988191b61a5d96232</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Alobaidi S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 3Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 4Doctor Soliman Fakeeh Hospital, Rheumatology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 5Medical College, Umm Alqura University (UQU), Makkah, 21441, Saudi ArabiaCorrespondence: Sami AlobaidiDepartment of Medicine, University of Jeddah, Jeddah, Saudi ArabiaEmail salobaidiuj.edu.saContext: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). Although it is associated with CKD incidence and progression, treating asymptomatic hyperuricemia with uric acid-lowering agents is still debatable.Aim of Work: determine the rate of non-classical prescription of allopurinol in CKD patients.Settings and Design: This was a retrospective study of adult patients prescribed allopurinol with CKD (stages 2&ndash; 5) in Doctor Soliman Fakeeh Hospital (DSFH) Jeddah, Saudi Arabia, from 1/1/2016 to 1/1/2017.Subjects and Methods: Eligible patients were identified from the hospital&rsquo;s pharmacy system and cross-referenced with the electronic health records. Demographic data, laboratory results and indication as recorded by the prescribing physician were extracted. Prescriptions with no indication were categorized based on the uric acid levels. Hyperuricemia was documented as mild (6&ndash; 10 mg/dL in females and 7&ndash; 13 mg/dL in males) and severe (&gt; 13mg/dL in men and &gt; 10mg/dL in women).Statistical Analysis Used: Descriptive statistics (frequencies, percentages).Results: From the 594 identified patients, 464 (78.1%) were males. A third of prescriptions (209/594) had no indication, 43.5% of which (91/209) had no documented uric acid levels, and 16.3% (34/209) had normal levels. Including patients with undocumented indication, 64.2% (381/594) were prescribed allopurinol for hyperuricemia, 86.4% of which (329/381) had mild hyperuricemia, and only 13.6% (52/381) had severe hyperuricemia. Other indications included malignancy-related disorders (6.2%, 37/594), gouty arthritis (5.2%, 31/594), and stones of unknown aetiology (3.4%, 20/594).Conclusion: The percentage of allopurinol prescription to patients with CKD without a clear indication in our centre was markedly high. This might increase the risk for side effects with no evidence-based benefits.Keywords: allopurinol, gout, hyperuricemia, hyperuricosuria, over prescription, chronic kidney disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">allopurinol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gout</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hyperuricemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hyperuricosuria</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">over prescription</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic kidney disease.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dwid N</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shikh Souk K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cheikh M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mandurah A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Al-Khatib K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ahmed A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Almoallim H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of General Medicine</subfield><subfield code="d">Dove Medical Press, 2008</subfield><subfield code="g">(2021), Seite 1141-1146</subfield><subfield code="w">(DE-627)578539691</subfield><subfield code="w">(DE-600)2452220-X</subfield><subfield code="x">11787074</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2021</subfield><subfield code="g">pages:1141-1146</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/de67e80ae4ad454988191b61a5d96232</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/the-pattern-of-allopurinol-prescription-among-chronic-kidney-disease-p-peer-reviewed-article-IJGM</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-7074</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2021</subfield><subfield code="h">1141-1146</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Alobaidi S |
spellingShingle |
Alobaidi S misc R5-920 misc allopurinol misc gout misc hyperuricemia misc hyperuricosuria misc over prescription misc chronic kidney disease. misc Medicine (General) The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience |
authorStr |
Alobaidi S |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)578539691 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
R5-920 |
illustrated |
Not Illustrated |
issn |
11787074 |
topic_title |
R5-920 The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience allopurinol gout hyperuricemia hyperuricosuria over prescription chronic kidney disease |
topic |
misc R5-920 misc allopurinol misc gout misc hyperuricemia misc hyperuricosuria misc over prescription misc chronic kidney disease. misc Medicine (General) |
topic_unstemmed |
misc R5-920 misc allopurinol misc gout misc hyperuricemia misc hyperuricosuria misc over prescription misc chronic kidney disease. misc Medicine (General) |
topic_browse |
misc R5-920 misc allopurinol misc gout misc hyperuricemia misc hyperuricosuria misc over prescription misc chronic kidney disease. misc Medicine (General) |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
International Journal of General Medicine |
hierarchy_parent_id |
578539691 |
hierarchy_top_title |
International Journal of General Medicine |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)578539691 (DE-600)2452220-X |
title |
The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience |
ctrlnum |
(DE-627)DOAJ048712639 (DE-599)DOAJde67e80ae4ad454988191b61a5d96232 |
title_full |
The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience |
author_sort |
Alobaidi S |
journal |
International Journal of General Medicine |
journalStr |
International Journal of General Medicine |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2021 |
contenttype_str_mv |
txt |
container_start_page |
1141 |
author_browse |
Alobaidi S Dwid N Shikh Souk K Cheikh M Mandurah A Al-Khatib K Ahmed A Almoallim H |
class |
R5-920 |
format_se |
Elektronische Aufsätze |
author-letter |
Alobaidi S |
author2-role |
verfasserin |
title_sort |
pattern of allopurinol prescription among chronic kidney disease patients in a tertiary care centre: a single-centre experience |
callnumber |
R5-920 |
title_auth |
The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience |
abstract |
Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 3Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 4Doctor Soliman Fakeeh Hospital, Rheumatology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 5Medical College, Umm Alqura University (UQU), Makkah, 21441, Saudi ArabiaCorrespondence: Sami AlobaidiDepartment of Medicine, University of Jeddah, Jeddah, Saudi ArabiaEmail salobaidiuj.edu.saContext: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). Although it is associated with CKD incidence and progression, treating asymptomatic hyperuricemia with uric acid-lowering agents is still debatable.Aim of Work: determine the rate of non-classical prescription of allopurinol in CKD patients.Settings and Design: This was a retrospective study of adult patients prescribed allopurinol with CKD (stages 2– 5) in Doctor Soliman Fakeeh Hospital (DSFH) Jeddah, Saudi Arabia, from 1/1/2016 to 1/1/2017.Subjects and Methods: Eligible patients were identified from the hospital’s pharmacy system and cross-referenced with the electronic health records. Demographic data, laboratory results and indication as recorded by the prescribing physician were extracted. Prescriptions with no indication were categorized based on the uric acid levels. Hyperuricemia was documented as mild (6– 10 mg/dL in females and 7– 13 mg/dL in males) and severe (> 13mg/dL in men and > 10mg/dL in women).Statistical Analysis Used: Descriptive statistics (frequencies, percentages).Results: From the 594 identified patients, 464 (78.1%) were males. A third of prescriptions (209/594) had no indication, 43.5% of which (91/209) had no documented uric acid levels, and 16.3% (34/209) had normal levels. Including patients with undocumented indication, 64.2% (381/594) were prescribed allopurinol for hyperuricemia, 86.4% of which (329/381) had mild hyperuricemia, and only 13.6% (52/381) had severe hyperuricemia. Other indications included malignancy-related disorders (6.2%, 37/594), gouty arthritis (5.2%, 31/594), and stones of unknown aetiology (3.4%, 20/594).Conclusion: The percentage of allopurinol prescription to patients with CKD without a clear indication in our centre was markedly high. This might increase the risk for side effects with no evidence-based benefits.Keywords: allopurinol, gout, hyperuricemia, hyperuricosuria, over prescription, chronic kidney disease |
abstractGer |
Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 3Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 4Doctor Soliman Fakeeh Hospital, Rheumatology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 5Medical College, Umm Alqura University (UQU), Makkah, 21441, Saudi ArabiaCorrespondence: Sami AlobaidiDepartment of Medicine, University of Jeddah, Jeddah, Saudi ArabiaEmail salobaidiuj.edu.saContext: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). Although it is associated with CKD incidence and progression, treating asymptomatic hyperuricemia with uric acid-lowering agents is still debatable.Aim of Work: determine the rate of non-classical prescription of allopurinol in CKD patients.Settings and Design: This was a retrospective study of adult patients prescribed allopurinol with CKD (stages 2– 5) in Doctor Soliman Fakeeh Hospital (DSFH) Jeddah, Saudi Arabia, from 1/1/2016 to 1/1/2017.Subjects and Methods: Eligible patients were identified from the hospital’s pharmacy system and cross-referenced with the electronic health records. Demographic data, laboratory results and indication as recorded by the prescribing physician were extracted. Prescriptions with no indication were categorized based on the uric acid levels. Hyperuricemia was documented as mild (6– 10 mg/dL in females and 7– 13 mg/dL in males) and severe (> 13mg/dL in men and > 10mg/dL in women).Statistical Analysis Used: Descriptive statistics (frequencies, percentages).Results: From the 594 identified patients, 464 (78.1%) were males. A third of prescriptions (209/594) had no indication, 43.5% of which (91/209) had no documented uric acid levels, and 16.3% (34/209) had normal levels. Including patients with undocumented indication, 64.2% (381/594) were prescribed allopurinol for hyperuricemia, 86.4% of which (329/381) had mild hyperuricemia, and only 13.6% (52/381) had severe hyperuricemia. Other indications included malignancy-related disorders (6.2%, 37/594), gouty arthritis (5.2%, 31/594), and stones of unknown aetiology (3.4%, 20/594).Conclusion: The percentage of allopurinol prescription to patients with CKD without a clear indication in our centre was markedly high. This might increase the risk for side effects with no evidence-based benefits.Keywords: allopurinol, gout, hyperuricemia, hyperuricosuria, over prescription, chronic kidney disease |
abstract_unstemmed |
Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 3Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 4Doctor Soliman Fakeeh Hospital, Rheumatology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 5Medical College, Umm Alqura University (UQU), Makkah, 21441, Saudi ArabiaCorrespondence: Sami AlobaidiDepartment of Medicine, University of Jeddah, Jeddah, Saudi ArabiaEmail salobaidiuj.edu.saContext: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). Although it is associated with CKD incidence and progression, treating asymptomatic hyperuricemia with uric acid-lowering agents is still debatable.Aim of Work: determine the rate of non-classical prescription of allopurinol in CKD patients.Settings and Design: This was a retrospective study of adult patients prescribed allopurinol with CKD (stages 2– 5) in Doctor Soliman Fakeeh Hospital (DSFH) Jeddah, Saudi Arabia, from 1/1/2016 to 1/1/2017.Subjects and Methods: Eligible patients were identified from the hospital’s pharmacy system and cross-referenced with the electronic health records. Demographic data, laboratory results and indication as recorded by the prescribing physician were extracted. Prescriptions with no indication were categorized based on the uric acid levels. Hyperuricemia was documented as mild (6– 10 mg/dL in females and 7– 13 mg/dL in males) and severe (> 13mg/dL in men and > 10mg/dL in women).Statistical Analysis Used: Descriptive statistics (frequencies, percentages).Results: From the 594 identified patients, 464 (78.1%) were males. A third of prescriptions (209/594) had no indication, 43.5% of which (91/209) had no documented uric acid levels, and 16.3% (34/209) had normal levels. Including patients with undocumented indication, 64.2% (381/594) were prescribed allopurinol for hyperuricemia, 86.4% of which (329/381) had mild hyperuricemia, and only 13.6% (52/381) had severe hyperuricemia. Other indications included malignancy-related disorders (6.2%, 37/594), gouty arthritis (5.2%, 31/594), and stones of unknown aetiology (3.4%, 20/594).Conclusion: The percentage of allopurinol prescription to patients with CKD without a clear indication in our centre was markedly high. This might increase the risk for side effects with no evidence-based benefits.Keywords: allopurinol, gout, hyperuricemia, hyperuricosuria, over prescription, chronic kidney disease |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
title_short |
The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience |
url |
https://doaj.org/article/de67e80ae4ad454988191b61a5d96232 https://www.dovepress.com/the-pattern-of-allopurinol-prescription-among-chronic-kidney-disease-p-peer-reviewed-article-IJGM https://doaj.org/toc/1178-7074 |
remote_bool |
true |
author2 |
Dwid N Shikh Souk K Cheikh M Mandurah A Al-Khatib K Ahmed A Almoallim H |
author2Str |
Dwid N Shikh Souk K Cheikh M Mandurah A Al-Khatib K Ahmed A Almoallim H |
ppnlink |
578539691 |
callnumber-subject |
R - General Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
callnumber-a |
R5-920 |
up_date |
2024-07-03T19:16:54.762Z |
_version_ |
1803586596779327488 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ048712639</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308135547.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ048712639</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJde67e80ae4ad454988191b61a5d96232</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Alobaidi S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sami Alobaidi,1 Naji Dwid,2 Khaldoun Shikh Souk,3 Mohamed Cheikh,4 Ahmed Mandurah,3 Khaled Al-Khatib,3 Ans Ahmed,3 Hani Almoallim5 1Department of Medicine, University of Jeddah, Jeddah, Saudi Arabia; 2Doctor Soliman Fakeeh Hospital, Nephrology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 3Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 4Doctor Soliman Fakeeh Hospital, Rheumatology Fellow for Saudi Commission for Health Specialties, Jeddah, Saudi Arabia; 5Medical College, Umm Alqura University (UQU), Makkah, 21441, Saudi ArabiaCorrespondence: Sami AlobaidiDepartment of Medicine, University of Jeddah, Jeddah, Saudi ArabiaEmail salobaidiuj.edu.saContext: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD). Although it is associated with CKD incidence and progression, treating asymptomatic hyperuricemia with uric acid-lowering agents is still debatable.Aim of Work: determine the rate of non-classical prescription of allopurinol in CKD patients.Settings and Design: This was a retrospective study of adult patients prescribed allopurinol with CKD (stages 2&ndash; 5) in Doctor Soliman Fakeeh Hospital (DSFH) Jeddah, Saudi Arabia, from 1/1/2016 to 1/1/2017.Subjects and Methods: Eligible patients were identified from the hospital&rsquo;s pharmacy system and cross-referenced with the electronic health records. Demographic data, laboratory results and indication as recorded by the prescribing physician were extracted. Prescriptions with no indication were categorized based on the uric acid levels. Hyperuricemia was documented as mild (6&ndash; 10 mg/dL in females and 7&ndash; 13 mg/dL in males) and severe (&gt; 13mg/dL in men and &gt; 10mg/dL in women).Statistical Analysis Used: Descriptive statistics (frequencies, percentages).Results: From the 594 identified patients, 464 (78.1%) were males. A third of prescriptions (209/594) had no indication, 43.5% of which (91/209) had no documented uric acid levels, and 16.3% (34/209) had normal levels. Including patients with undocumented indication, 64.2% (381/594) were prescribed allopurinol for hyperuricemia, 86.4% of which (329/381) had mild hyperuricemia, and only 13.6% (52/381) had severe hyperuricemia. Other indications included malignancy-related disorders (6.2%, 37/594), gouty arthritis (5.2%, 31/594), and stones of unknown aetiology (3.4%, 20/594).Conclusion: The percentage of allopurinol prescription to patients with CKD without a clear indication in our centre was markedly high. This might increase the risk for side effects with no evidence-based benefits.Keywords: allopurinol, gout, hyperuricemia, hyperuricosuria, over prescription, chronic kidney disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">allopurinol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">gout</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hyperuricemia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hyperuricosuria</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">over prescription</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">chronic kidney disease.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dwid N</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shikh Souk K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cheikh M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mandurah A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Al-Khatib K</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ahmed A</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Almoallim H</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of General Medicine</subfield><subfield code="d">Dove Medical Press, 2008</subfield><subfield code="g">(2021), Seite 1141-1146</subfield><subfield code="w">(DE-627)578539691</subfield><subfield code="w">(DE-600)2452220-X</subfield><subfield code="x">11787074</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2021</subfield><subfield code="g">pages:1141-1146</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/de67e80ae4ad454988191b61a5d96232</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/the-pattern-of-allopurinol-prescription-among-chronic-kidney-disease-p-peer-reviewed-article-IJGM</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-7074</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2021</subfield><subfield code="h">1141-1146</subfield></datafield></record></collection>
|
score |
7.400629 |